Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT. READ MORE

Author Insights

Recent research has uncovered a non-inferior, cost-effective alternative to standard therapy for autologous stem cell mobilization in multiple myeloma. The study’s author discusses his findings.

READ MORE

Conferences

Clinicians are now trying to treat multiple myeloma similar to leukemia.

READ MORE

Carol Ann Huff, MD, discusses how to best use newly-approved therapies for multiple myeloma.

READ MORE

Comparing autologous stem cell transplant with bortezomib, melphalan, and prednisone. 

READ MORE

J Code Updates

News

Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.

READ MORE

Lenalidomide maintenance therapy after autologous stem-cell transplantation prolongs the time to remission in patients with multiple myeloma.

READ MORE

Researchers compared the safety and efficacy of a certain therapy with conventional treatment for patients with relapsed or refractory multiple myeloma.

READ MORE

For patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma, dosing zoledronic acid every 12 weeks works as well as the standard dosing interval of every four weeks.

READ MORE

Research in Review

A recent cost-effectiveness analysis compared novel agents and chemotherapy for older Medicare patients with multiple myeloma.

READ MORE

According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

READ MORE

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.

READ MORE

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival by 14 months compared with patients who receive chemotherapy alone.

READ MORE

Slideshow

The US Food and Drug Administration (FDA) has approved many new drugs and indications for the treatment of cancer in the last 6 months. Review the drugs that were approved to treat specific forms of blood cancer and the results that led to the FDA decisions.  

READ MORE